




RealRate

PHARMACEUTICAL 2021

Mirati Therapeutics Inc.
Rank 110 of 409

MIRATI
THERAPEUTICS



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 209% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 5.5%, being 360% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	1,403,643
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	71,472
Liabilities, Non-Current	43,867
Other Assets	64,676
Other Compr. Net Income	-130
Other Expenses	0
Other Liabilities	0
Other Net Income	11,426
Property and Equipment	7,809
Research and Development	299,349
Revenues	13,398
Selling, General and Administrative Expense	83,412

Output Variable	Value in 1000 USD
Assets	1,476,128
Liabilities	115,339
Expenses	382,761
Stockholders Equity	1,360,789
Net Income	-357,937
Comprehensive Net Income	-358,002
Economic Capital Ratio	5.5%